BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and
BARCELONA, Spain—Although having a mutated MYC molecule is a distinguishing molecular factor in many solid tumors it has been considered “undruggable” — having a shortage of potential and actual mechanisms for cancer inhibition. But it now looks as though MYC could be a viable target for cancer drugs. A phase one study of a “pan-MYC inhibitor” OMO 103 has made promising findings in both safety and efficacy according to a findings given to the 2022 EORTC-NCI-AACR symposium.
First author of the study, Elena Garralda MD, Head of Early Drug Development Unit at Vall d’Hebron Hospital in Barcelona gave the Audio Journal of Oncology’s Peter Goodwin the details:
Related Episodes
AUDIO JOURNAL OF ONCOLOGY – ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy
ARROS-1 Study Finds ROS1 Tyrosine Kinase Inhibitor Has Promise as a Tumor Agnostic Therapy BARCELONA, Spain—Findings from a study of a new investigational therapy targeting the ROS-1 receptor tyrosine
AUDIO JOURNAL OF ONCOLOGY—Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study
Pan-AKT Inhibitor Tumor Agnostic Targeting was Safe and Effective in Phase One Study BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT i
AUDIO JOURNAL OF ONCOLOGY—Glioma in Adults: Next Generation Sequencing Validates BRAF Targeting
BARCELONA, Spain—Next generation sequencing is now an essential part of care for glioma in adults, according to research on BRAF targeting as treatment for this disease reported at the 2022 EORTC-NCI-